Patents by Inventor Frank Beurskens

Frank Beurskens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240317881
    Abstract: Antibody variants comprising one or more mutations in the Fc region, particularly anti-CD38 antibodies comprising a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino acid residues are numbered according to the EU index.
    Type: Application
    Filed: January 23, 2024
    Publication date: September 26, 2024
    Inventors: Bart DE GOEIJ, Grietje ANDRINGA, Frank BEURSKENS, Janine SCHUURMAN, David P.E. SATIJN, Tahamtan AHMADI
  • Publication number: 20240254252
    Abstract: Antibody variants for therapeutic use involving trogocytosis-mediated reduction of CD38 on CD38-expressing immunosuppressive cells; particularly CD38 antibody variants comprising one or more mutations in the Fc region, such a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino 5 acid residues are numbered according to the EU index.
    Type: Application
    Filed: July 15, 2019
    Publication date: August 1, 2024
    Inventors: Bart E. C. G. DE GOEIJ, Grietje ANDRINGA, Frank BEURSKENS, Janine SCHUURMAN, David SATIJN, Tahamtan AHMADI
  • Publication number: 20240252635
    Abstract: The disclosure relates to pharmaceutical compositions comprising CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The disclosure also relates to use of these pharmaceutical compositions for the treatment of cancer and other diseases.
    Type: Application
    Filed: October 4, 2019
    Publication date: August 1, 2024
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther C. W. BREIJ, Edward N. VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E. D. CHAMULEAU, Tuna MUTIS, Christian CIMANDER, Martin SAHLIN, Shan REN, Abbas RAZVI, Christoph GRAPENTIN
  • Patent number: 12049512
    Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: July 30, 2024
    Assignee: GENMAB B.V.
    Inventors: Paul Parren, Frank Beurskens, Rob N. De Jong, Aran Frank Labrijn, Janine Schuurman
  • Publication number: 20240117064
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: October 27, 2022
    Publication date: April 11, 2024
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D. CHAMULEAU, Tuna MUTIS
  • Publication number: 20240076397
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: October 27, 2023
    Publication date: March 7, 2024
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D. CHAMULEAU, Tuna MUTIS
  • Publication number: 20230399414
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: October 27, 2022
    Publication date: December 14, 2023
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D.CHAMULEAU, Tuna MUTIS
  • Publication number: 20230212301
    Abstract: The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: November 14, 2022
    Publication date: July 6, 2023
    Inventors: Andreea Ioan, Frank Beurskens, Rob N. de Jong, Janine Schuurman, Esther C. W. Breij, Isil Altintas, Pauline L. de Goeje, David Satijn, Peter Boross, Ugur Sahin, Friederike Gieseke, Alexander Muik, Kristina Schödel
  • Publication number: 20230107363
    Abstract: Described herein are polypeptides and antibodies comprising a variant Fc region. The variant Fc region provides for stabilized Fc-Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, while at the same time also having decreased complement-dependent cytotoxicity (CDC) and may also have decreased activation of other effector functions resulting from one or more amino acid modifications in the Fc region.
    Type: Application
    Filed: May 16, 2022
    Publication date: April 6, 2023
    Inventors: Rob DE JONG, Frank Beurskens, Marije Overdijk, Kristin STRUMANE, Janine Schuurman, Paul Parren
  • Publication number: 20230109496
    Abstract: The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: September 6, 2022
    Publication date: April 6, 2023
    Inventors: Andreea Ioan, Frank Beurskens, Rob N. de Jong, Janine Schuurman, Esther C. W. Breij, Isil Altintas, Pauline L. de Goeje, David Satijn, Peter Boross, Ugur Sahin, Friederike Gieseke, Alexander Muik, Kristina Schödel
  • Publication number: 20220411522
    Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind antigens of Death Receptors, which are members of the tumor necrosis factor (TNF) receptor Superfamily (TNFR-SF) with an intracellular death domain. The invention relates in particular to antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after target binding. The invention further relates to a combination of antibody molecules binding different epitopes on one or more specific Death Receptors. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
    Type: Application
    Filed: March 1, 2022
    Publication date: December 29, 2022
    Inventors: Frank BEURSKENS, Marije OVERDIJK, Rob DE JONG, David SATIJN, Kristin STRUMANE, Janine SCHUURMAN, Paul PARREN
  • Publication number: 20220411529
    Abstract: The invention relates to combination therapy involving two or more antibodies, wherein the Fc regions of the two antibodies have been modified such that hetero-oligomerization between the antibodies is strongly favored over self-oligomerization when antibodies are bound to their corresponding target antigens and such that hetero-oligomerization-independent effector functions of one or both antibodies are eliminated or strongly reduced. The invention also relates to antibodies, compositions, and kits suitable for use in the combination therapy of the invention.
    Type: Application
    Filed: November 6, 2020
    Publication date: December 29, 2022
    Inventors: Rob DE JONG, Frank BEURSKENS, Gijs ZOM, Janine SCHUURMAN, Xiaoguang XUE
  • Publication number: 20220396629
    Abstract: The present invention provides monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies.
    Type: Application
    Filed: May 26, 2022
    Publication date: December 15, 2022
    Inventors: Paul PARREN, Janine Schuurman, Tom Vink, Willem Karel Bleeker, Jan Van De Winkel, Patrick Van Berkel, Frank Beurskens
  • Patent number: 11512137
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: November 29, 2022
    Assignee: GENMAB HOLDING B.V.
    Inventors: Simone Oostindie, Frank Beurskens, Esther Breij, Edward Van Den Brink, Andreas Hollenstein, Marije Overdijk, Margaret Lindorfer, Ronald Taylor, Paul Parren, Hilma Van Der Horst, Martine E. D. Chamuleau, Tuna Mutis
  • Publication number: 20220332801
    Abstract: The present invention relates to antibody molecules that bind to Wall Teichoic Acid (WTA) or Capsular Polysaccharides (CP) such as Capsular Polysaccharides type 5 (CP5). The invention relates in particular to antibody molecules of the IgG isotype having a mutation in the Fc domain that enhances clustering of IgG molecules after target binding.
    Type: Application
    Filed: November 24, 2021
    Publication date: October 20, 2022
    Inventors: Annemarie KUIPERS, Kok VAN KESSEL, Frank BEURSKENS, Rob DE JONG, Kristin STRUMANE, Janine SCHUURMAN, Paul PARREN, Jos VAN STRIJP, Suzan ROOIJAKKERS
  • Publication number: 20220251231
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: November 23, 2021
    Publication date: August 11, 2022
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D. CHAMULEAU, Tuna MUTIS
  • Patent number: 11396553
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Grant
    Filed: July 22, 2021
    Date of Patent: July 26, 2022
    Assignee: GENMAB HOLDING B.V.
    Inventors: Simone Oostindie, Frank Beurskens, Esther Breij, Edward Van Den Brink, Andreas Hollenstein, Marije Overdijk, Margaret Lindorfer, Ronald Taylor, Paul Parren, Hilma Van Der Horst, Martine E. D. Chamuleau, Tuna Mutis
  • Publication number: 20210371539
    Abstract: The present invention relates to anti-CD37antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG, for use as a medicament in combination with anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG. The invention also relates to a novel composition of anti-CD37 antibodies having an Fc-Fc 5 interaction enhancing substitution and anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution. In particular, the invention relates to compositions wherein the anti-CD37 antibody binds human CD37 and the anti-CD20 antibody binds human CD20. The invention also relates to compositions where the composition is a pharmaceutical composition and the use of such compositions in treatment of cancer and other diseases.
    Type: Application
    Filed: June 24, 2019
    Publication date: December 2, 2021
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Ronald TAYLOR, Margaret LINDORFER, Hilma VAN DER HORST, Martine E. D. CHAMULEAU, Tuna MUTIS, Paul PARREN, Esther BREIJ
  • Patent number: 11180572
    Abstract: The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: November 23, 2021
    Assignee: GENMAB B.V.
    Inventors: Rob N. De Jong, Frank Beurskens, Paul Parren, Aran Frank Labrijn, Janine Schuurman, Arjen Vlug, Sandra Verploegen
  • Publication number: 20210355232
    Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.
    Type: Application
    Filed: July 22, 2021
    Publication date: November 18, 2021
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther BREIJ, Edward VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E.D. CHAMULEAU, Tuna MUTIS